Premaitha chief hails pre-natal test trial outcome

THE chief executive of a Manchester biotech company which has pioneered a test for Down’s Syndrome in unborn children which reduces the risk of miscarriage has welcomed news it could soon be more widely available on the NHS.

Dr Stephen Little, CEO of Premaitha Health, was reacting to trials at Great Ormond Street Hospital, which suggested the new test – for fragments of foetal DNA in a mother’s blood – could be cost effective.

Premaitha has led the way in the development of its IONA non... For the full story register now for free or login below...

Close